Here are six report highlights:
1. Misonix’s net sales totaled $23.1 million in FY 2016, reflecting a 4.2 percent increase over FY 2015.
2. The company experienced a net loss of $1.2 million in FY 2016.
3. On Jan. 31, 2017, the company’s cash balance totaled $12 million.
4. Misonix concluded a voluntary internal investigation, with the help of outside legal counsel, looking into the practice of an independent Chinese entity that distributed the company’s products in China. The investigation also looked into Misonix’s awareness of these business practices, which could fall under the Foreign Corrupt Practices Act.
5. Based on the internal investigation, Misonix reported its previously stated financial reports are correct.
6. Although the internal investigation is complete, Misonix told the U.S. Securities and Exchange Commission and Department of Justice that the government is still conducting its own investigation into the matter.
More articles on devices:
92% of HF10 therapy trial patients report lowered back and leg pain — 5 things to know
Arlington Orthopedic Associates 1st in Texas to use NUsurface Meniscus Implant — 7 observations
Reston Hospital Center adds Mazor X to spinal surgery program — 4 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
